Pacitti brings an extensive background in clinical and preclinical development services, having worked for over 15 years in clinical related development and research laboratories, clinical research organizations (CRO), preclinical development services as well as contract clinical supply services. She brings a substantial depth of knowledge and expertise in PCI’s clinical supply specializations including drug development and clinical scale manufacturing, analytical laboratory services, clinical trial packaging and labeling, as well as global logistical services including storage, distribution, and returns management.
Commenting on her appointment, Tim Roberts, North America Business Development Director, stated: “We are delighted to welcome Anita to our team. She brings a great deal of experience and a proven track record in business development across the clinical outsourcing sector. Her background will be invaluable to our clients. She delivers considerable insight as our clients look to execute their global studies more efficiently and cost effectively.”
Pacitti stated: “I’m excited to join PCI Clinical Services and I am looking forward to applying my previous experience in my new role. I have a long history of working in life sciences and in developing and maintaining strong long-term client relationships. I look forward to leveraging my experience and the considerable expertise at PCI to deliver clients the industry’s leading experience.”
PCI has recently announced considerable investment in its clinical trials business over the past few months including the expansion of its Cold Chain infrastructure at its 93,000 square foot North American clinical logistics facility in Rockford IL, adding cryogenic storage to complement its extensive refrigerated and frozen on-site storage. In addition the company announced a significant site expansion of its Bridgend, UK clinical center of excellence, which also specializes in a broad range of temperature controlled storage and distribution capabilities including cryogenic storage, complementing the North American site.
This follows the company’s announcement of their site expansion to its drug development and clinical trial manufacturing center of excellence in Tredegar, UK, including the purchase of a fully contained Excelodose 600 unit for contained development of potent compounds in early phase clinical study.
To find out more about PCI, please visit www.pciservices.com.